Investors may be wondering whether ADMA Biologics at around US$10.74 is priced for its future potential or already reflects ...

ADMA stock plunges after a short report, but strong Asceniv demand, rising revenues, and margin expansion signal potential ...

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from ...

Adma Biologics (ADMA) closed at $10.65 in the latest trading session, marking a +1.53% move from the prior day. This move outpaced the S&P 500's daily gain of 0.8%. Meanwhile, the Dow experienced a ...

ADMA announced the FDA's approval of its yield enhancement process. The company's yield enhancement process has demonstrated the ability to increase production yields by approximately 20%.

NEW YORK CITY, NY / ACCESS Newswire / April 2, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income (1) of ...

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, ...

ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's ...